Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-03-11
2011-11-15
Chu, Yong (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S422000, C514S424000, C548S139000, C548S524000, C548S543000
Reexamination Certificate
active
08058293
ABSTRACT:
Disclosed herein are compounds of formula (I)wherein R1, R2, R3, R25a, R26a, X, and n are as defined in the specification. Pharmaceutical compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and pharmaceutical compositions are also described.
REFERENCES:
patent: 5468722 (1995-11-01), Shibata et al.
patent: 7511013 (2009-03-01), Molino et al.
patent: 7514068 (2009-04-01), Tung
patent: 7521421 (2009-04-01), Naicker et al.
patent: 7528131 (2009-05-01), Persichetti et al.
patent: 7531685 (2009-05-01), Czarnik
patent: 7534814 (2009-05-01), Ascher et al.
patent: 7538189 (2009-05-01), Naicker et al.
patent: 7872033 (2011-01-01), Carroll et al.
patent: 7875639 (2011-01-01), Florjancic et al.
patent: 7875640 (2011-01-01), Kolasa et al.
patent: 2004/0259912 (2004-12-01), Matsumoto et al.
patent: 2006/0199817 (2006-09-01), Tasker et al.
patent: 2009/0082471 (2009-03-01), Czarnik
patent: 2009/0088416 (2009-04-01), Czarnik
patent: 2009/0093422 (2009-04-01), Tung et al.
patent: 2009/0105147 (2009-04-01), Masse
patent: 2009/0105305 (2009-04-01), Butlin et al.
patent: 2009/0105307 (2009-04-01), Galley et al.
patent: 2009/0105338 (2009-04-01), Czarnik
patent: 2009/0111840 (2009-04-01), Herold et al.
patent: 2009/0118238 (2009-05-01), Czarnik
patent: 2009/0131363 (2009-05-01), Harbeson
patent: 2009/0131485 (2009-05-01), Liu et al.
patent: 2009/0137457 (2009-05-01), Harbeson
patent: 2010/0041720 (2010-02-01), Carroll et al.
patent: 1820504 (2007-08-01), None
patent: WO9507271 (1995-03-01), None
patent: WO9710223 (1997-03-01), None
patent: WO02102232 (2002-12-01), None
patent: WO2005099353 (2005-10-01), None
patent: WO2006008754 (2006-01-01), None
patent: WO-2007140385 (2007-12-01), None
patent: WO2007140385 (2008-02-01), None
patent: WO-2008121558 (2008-10-01), None
patent: WO2008130953 (2008-10-01), None
patent: WO2009048936 (2009-04-01), None
patent: WO2010019547 (2010-02-01), None
Wu and Farrelly, Toxicology 236:1-6, 2007.
Vippagunta et al., Advanced Drug Delivery Reviews, vol. 48, p. 3-26 ( on p. 3), 2001.
“IUPAC Commission on Nomenclature of Organic Chemistry—Rules for the Nomenclature of Organic Chemistry, Section E: Stereochemistry (Recommendations 1974),” Pure Appl Chem, 1976, 13-30, vol. 45.
Arevalo-Martin, A., et al., “Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis,” Journal of Neuroscience, 2003, 2511-2516, vol. 23, No. 7.
Benito, C. et al., “Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains,” Journal of Neuroscience, 2003, 11136-11141, vol. 23—Issue 35.
Berge, S.M. et al., “Pharmaceutical Salts,” J Pharmaceutical Sciences, 1977, 1-19, vol. 66.
Bouchard, J-F et al., “Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart”, Life Sciences, 2003, 1859-1870, vol. 72.
Boyle, W.J. et al., “Osteoclast differentiation and activation,” (Binary/Image), 2003, 337-342, vol. 423.
Brennan, T.J. et al., “Characterization of a rat model of incisional pain,” (Binary/Image), 1996, 493-501, vol. 64.
Buckley, N.E. et al., “Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB receptor,” European Journal of Pharmacology, 2000, 141-149, vol. 396.
Carlisle, S.J. et al., “Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation,” International Immunopharmacology, 2002, 69, vol. 2.
Carrier, E.J. et al., “Endocannabinoids in Neuroimmunology and Stress,” Current Drug Targets—CNS & Neurological Disorders, 2005, 657-665, vol. 4.
Casanova, M.L. et al., “Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors,” Journal of Clinical Investigation, 2003, 43-50, vol. 111.
Chaplan, S.R. et al., “Quantitative assessment of tactile allodynia in the rat paw,” Journal of Neuroscience Methods, 1994, 55-63, vol. 53.
Cichewicz, D.L. et al., “Synergistic interactions between cannabinoid and opioid analgesics,” Life Sciences, 2004, 1317-1324, vol. 74.
Clayton, N. et al., “CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain,” (Binary/Image), 2002, 253-260, vol. 96.
Dixon, W.J. “Efficient analysis of experimental observations,” Annual Review of Pharmacology and Toxicology, 1980, 441-462, vol. 20.
Filippo, C.D. et al., “Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN,” Journal of Leukocyte Biology, 2004, 453-459, vol. 75.
Galiégue, et al., “Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations,” European Journal of Biochemistry, 1995, 54-61, vol. 232.
Greene, T.W. et al., “Protective Groups in Organic Synthesis”, 1999, 3 rd Ed, 494-653.
Grotenhermen, F. et al., “IACM 2nd Conference on Cannabinoids in Medicine,” Expert Opinion in Pharmacotherapy, 2003, 2367-2371, vol. 4—Issue 12.
Hanus, L. et al., “HU-308: A specific agonist for CB 2, a peripheral cannabinoid receptor,” Proceedings of the National Academy of Science, 1999, 14228-14233, vol. 96.
Hohmann, A.G. et al., “Selective Activation of Cannabinoid CB2 Receptors Suppresses Hyperalgesia Evoked by Intradermal Capsaicin,” Journal of Pharmacology and Experimental Therapeutics, 2004, 446-453, vol. 308.
Ibrahim, M.M. et al., “Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS,” Proceedings of the National Academy of Science, 2003, 10529-10533, vol. 100—Issue 18.
Ibrahim, M.M. et al., “CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids,” Proceedings of the National Academy of Science, 2005, 3093-3098, vol. 102—Issue 8.
Ihenetu, K. et al., “Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids,” European Journal of Pharmacology, 2003, 207-215, vol. 458.
Joshi S.K. et al., “Comparison of Antinociceptive Actoins of Standard Analgesics in Attenuating Capsaicin and Nerve-Injury-Induced Mechanical Hypersensitivty,” Neurosci, 587-596, vol. 143, (2006).
Julien, B, et al., “Antifibrogenic Role of the Cannabinoid Receptor CB2 in the Liver,” Gastroenterology, 2005, 742-755, vol. 128.
Karsak, M, et al., “Cannabinoid receptor type 2 gene is associated with human osteoporosis,” Human Molecular Genetics, 2005, 3389-3396, vol. 14—Issue 22.
Lepicier, P. et al., “Endocannabinoids protect the rat isolated heart against ischaemia,” British Journal of Pharmacology, 2003, 805-815, vol. 139.
Lotersztajn, S. et al., “Hepatic Fibrosis: Molecular Mechanisms and Drug Targets,” Annual Review of Pharmacology and Toxicology, 2005, 605-628, vol. 45.
Malan, T.P. et al., “CB2 cannabinoid receptor-mediated peripheral antinociception,” (Binary/Image), 2001, 239-245, vol. 93.
Maresz, K, et al., “Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli,” Journal of Neurochemistry, 2005, 437-445, vol. 95.
Mathison, R, et al., “Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats,” British Journal of Pharmacology, 2004, 1247-1254, vol. 142.
McKallip, R.J. et al., “Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease,” (Binary/Image), 2002, 627-634, vol. 15—Issue 2.
Nackley, A.G. et al., “Select
Carroll William A.
Frost Jennifer M.
Kolasa Teodozyj
Latshaw Steven P.
Medrano Arturo Perez
Abbott Laboratories
Chu Yong
Gettel Nancy J.
Parial Andrew M.
Srivastava Sonali
LandOfFree
Compounds as cannabinoid receptor ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds as cannabinoid receptor ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds as cannabinoid receptor ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4308176